Status:
UNKNOWN
Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis
Lead Sponsor:
St. Antonius Hospital
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Boehringer Ingelheim
Conditions:
Pulmonary Fibrosis Idiopathic Familial
Eligibility:
All Genders
18+ years
Brief Summary
In this study the prognostic value of the current screening parameters for familial pulmonary fibrosis (FPF) will be investigated by looking at the screenings of 200 first-degree relatives of patients...
Detailed Description
Familial pulmonary fibrosis (FPF) is a fatal lung disease that is often not diagnosed until a significant portion of the lung function is lost. Median survival after diagnosis is 3 to 5 years. As trea...
Eligibility Criteria
Inclusion
- Asymptomatic first-degree relative of patients with familial pulmonary fibrosis (FPF)
Exclusion
- A previous diagnosis of interstitial lung disease (ILD)
- Minors (aged \<18 years)
- Pregnant
- Note: woman who are pregnant at the start of the study or at the time of the HRCT are not allowed to participate. If a participant gets pregnant at a later stage during the study, she will not be excluded from the study. To be able to account for a potential effect of pregnancy during data analysis, female participants can be asked if they are pregnant at every visit.
Key Trial Info
Start Date :
June 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05367349
Start Date
June 16 2021
End Date
September 1 2025
Last Update
May 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Antonius Hospital
Nieuwegein, Netherlands, 3435CM